Colchicine plus rosuvastatin - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.81 [0.48, 1.36]< 10%1 study (1/-)78.8 %NAnot evaluable crucial-
deaths 0.81 [0.48, 1.36]< 10%1 study (1/-)78.8 %NAnot evaluable crucial-
mechanical ventilation 0.85 [0.68, 1.06]< 10%1 study (1/-)92.4 %NAnot evaluable important-
ICU admission 0.99 [0.56, 1.75]< 10%1 study (1/-)51.4 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.